1.广州中医药大学中药学院,广东 广州 510006
2.广州中医药大学第二附属医院Ⅰ期临床研究室,广东 广州 510120
3.热带生物资源教育部重点实验室 / 海南大学药学院,海南 海口 570228
黄尚瑛(1999年生),女;研究方向:天然活性小分子的发现与优化;E-mail:20221110765@stu.gzucm.edu.cn
曹影影(1990年生),女;研究方向:中药药理学;E-mail:caoyingying@gzucm.edu.cn
何细新(1972年生),男;研究方向:天然活性小分子的发现与优化;E-mail:mark07@gzucm.edu.cn
网络出版日期:2025-01,
收稿日期:2024-12-21,
录用日期:2025-01-06
移动端阅览
黄尚瑛, 刘兴福, 陈思竹, 等. 芒果苷元衍生物的设计合成及其抑制磷酸二酯酶4活性[J/OL]. 中山大学学报(自然科学版)(中英文), 2025,1-12.
HUANG SHANGYING, LIU XINGFU, CHEN SIZHU, et al. Design and synthesis of norathyriol derivatives and their inhibition of phosphodiesterase 4 activity. [J/OL]. Acta scientiarum naturalium universitatis sunyatseni, 2025, 1-12.
黄尚瑛, 刘兴福, 陈思竹, 等. 芒果苷元衍生物的设计合成及其抑制磷酸二酯酶4活性[J/OL]. 中山大学学报(自然科学版)(中英文), 2025,1-12. DOI: 10.13471/j.cnki.acta.snus.ZR20240361.
HUANG SHANGYING, LIU XINGFU, CHEN SIZHU, et al. Design and synthesis of norathyriol derivatives and their inhibition of phosphodiesterase 4 activity. [J/OL]. Acta scientiarum naturalium universitatis sunyatseni, 2025, 1-12. DOI: 10.13471/j.cnki.acta.snus.ZR20240361.
基于芒果苷元(norathyriol)氧杂蒽酮骨架,以芒果苷为起始原料开展结构修饰,经脱去2-糖基、2,3-环合、6,7-取代反应,设计合成了16个衍生物;采用[
3
H]标记液体闪烁计数法,评价衍生物体外抑制磷酸二酯酶4(PDE4)活性;运用Auto-Dock及pymol软件分析强抑制活性衍生物
4
与PDE4靶点蛋白的结合模式。结果表明,所得衍生物对PDE4的抑制活性较芒果苷元均有较大提升,其中衍生物
4
的抑制活性最高(IC
50
=358 nmol/L),对接显示结构中吡喃环与Gln-369形成氢键作用,6-位甲基环丙烷取代基与周围的疏水氨基酸形成疏水相互作用。
Derivatives of Norathyriol were designed and synthesized in this study, and their phosphodiesterase4(PDE4) inhibitory activities were evaluated
in vitro
. Mangiferin was used as the starting material for structural modification, and sixteen derivatives were prepared through 2-deglycosylation, 2,3-cyclic synthesis, and 6,7-substitution reactions and other methods. The PDE4 inhibitory activities of these compounds were evaluat
ed
in vitro
by [
3
H] liquid scintillation counting method. Among these compounds, derivative
4
has the highest inhibitory activity (IC
50
=358 nmol/L). The docking display structure showed that the pyran ring could form hydrogen bonds with Gln-369, and the 6-methyl cyclopropane could form hydrophobic interactions with surrounding hydrophobic amino acids.
芒果苷元衍生物磷酸二酯酶4抑制剂
norathyriolderivativesphosphodiesterase 4inhibitor
邓金辉, 黄悦, 梁津豪, 等, 2022. α-倒捻子素衍生物合成及其抑制磷酸二酯酶4活性研究[J].中山大学学报(自然科学版)(中英文), 61(3):53-61.
周鹏飞, 侯爱君, 王洋, 2018. Cudratricusxanthone B的全合成[J]. 有机化学, 38(1): 156-161.
AHN S, YUN H, HAN Y T, 2018. An improved C-deglycosylation of mangiferin to norathyriol[J]. Org Prep Proced Int, 50(1):91-94.
CHEN C H, LIN J Y, LIN C N, et al, 1992. Inhibition of angiotensin-I-converting enzyme by tetrahydroxyxanthones isolated from Tripterospermum lanceolatum[J]. J Nat Prod,55(5):691-695.
DU B, LUO M, REN C, et al, 2023. PDE4 inhibitors for disease therapy: Advances and future perspective[J]. Future Med Chem, 15(13):1185-1207.
FU W M, ZHANG J F, WANG H, et al, 2012. Apoptosis induced by 1,3,6,7-tetrahydroxyxanthone in Hepatocellular carcinoma and proteomic analysis[J]. Apoptosis,17(8):842-851.
GONTIJO V S, DE SOUZA T C, ROSA I A, et al. Isolation and evaluation of the antioxidant activity of phenolic constituents of the Garcinia brasiliensis epicarp[J]. Food Chem, 2012, 132(3):1230-1235.
GUO J, XU C, XUE R, et al, 2015. Cytotoxic activities of chemical constituents from rhizomes of Anemarrhena asphodeloides and their analogues[J]. Arch Pharm Res,38(5):598-603.
HSU M F, LIN C N, LU M C, et al, 2004. Inhibition of the arachidonic acid cascade by norathyriol via blockade of cyclooxygenase and lipoxygenase activity in neutrophils[J]. Naunyn Schmiedebergs Arch Pharmacol,369(5):507-515.
HSU M F, RAUNG S L, TSAO L T, et al, 1997. Examination of the inhibitory effect of norathyriol in formylmethionyl-leucyl-phenylalanine-induced respiratory burst in rat neutrophils[J]. Free Radic Biol Med,23(7):1035-1045.
JIANG H Z, QUAN X F, TIAN W X, et al, 2010. Fatty acid synthase inhibitors of phenolic constituents isolated from Garcinia mangostana[J]. Bioorg Med Chem Lett, 20(20):6045-6047.
JIN J, MAZZACUVA F, CROCETTI L, et al, 2023. PDE4 inhibitors: Profiling hits through the multitude of structural classes[J]. Int J Mol Sci, 24(14):11518.
JYOTSHNA, KHARE P, SHANKER K, 2016. Mangiferin: A review of sources and interventions for biological activities[J]. BioFactors, 42(5):504-514.
LI G, HE D, CAI X, et al, 2023. Advances in the development of phosphodiesterase-4 inhibitors[J]. Eur J Med Chem, 250:115195.
LI J, LI X, HE Z, ZHOU K, et al, 2012. Norathyriol suppresses transformation in JB6 P+ cells by the inhibition of Akt[J]. J Cancer Res Ther,8(4):561-564.
LIANG J H, HUANG Y Y, ZHOU Q, et al, 2020. Discovery and optimization of α-mangostin derivatives as novel PDE4 inhibitors for the treatment of vascular dementia[J]. J Med Chem, 63(6):3370-3380.
LIN C N, CHANG C H, ARISAWA M, et al, 1982. A xanthone glycoside from Tripterospermum taiwanense and rutin from Gentiana flavo-maculata[J]. Phytochemistry, 21:948-949.
LIN C N, LIOU S S, KO F N, et al, 1992. Gamma-pyrone compounds. II: Synthesis and antiplatelet effects of tetraoxygenated xanthones[J]. J Pharm Scix,81(11):1109-1112.
LIN H, TU C, NIU Y, et al, 2019. Dual actions of norathyriol as a new candidate hypouricaemic agent: Uricosuric effects and xanthine oxidase inhibition[J]. Eur J Pharmaco,853:371-380.
LIU H B, QUAN W, YUE H, et al, 2022. Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases[J]. Eur J Med Chem, 242:114631.
LIU H, WANG K, TANG Y, et al, 2011. Structure elucidation of in vivo and in vitro metabolites of mangiferin[J]. J Pharm Biomed Anal, 55(5):1075-1082.
MEECHAI I, PHUPONG W, CHUNGLOK W, et al, 2016. Anti-radical activities of xanthones and flavonoids from Garcinia Schomburgkiana[J]. Int J Pharm Pharm Scix, 8:235-238.
NIU Y, LIU J, LIU H Y, et al, 2016. Hypouricaemic action of mangiferin results from metabolite norathyriol via inhibiting xanthine oxidase activity[J]. Pharm Biol;54(9):1680-1686.
NORO T, UENO A, MIZUTANI M, et al, 1984. Inhibitors of xanthine oxidase from Athyrium mesosorum[J]. Chem Pharm Bull (Tokyo);32(11):4455-4459.
PAGÈS L, GAVALDÀ A, LEHNER M D, 2009. PDE4 inhibitors: A review of current developments(2005-2009)[J]. Expert Opin Ther Pat, 19(11):1501-1519.
SANUGUL K, AKAO T, LI Y, et al, 2005. Isolation of a human intestinal bacterium that transforms mangiferin to norathyriol and inducibility of the enzyme that cleaves a C-glucosyl bond[J]. Biol Pharm Bull, 28(9):1672-1678.
TENG C M, KO F N, WANG J P, et al, 1989. Antihaemostatic and antithrombotic effect of some antiplatelet agents isolated from Chinese herbs[J]. J Pharm Pharmacolx,43(9):667-669.
TENG C M, LIN C N, KO F N, et al, 1991. Novel inhibitory actions on platelet thromboxane and inositolphosphate formation by xanthones and their glycosides[J], Biochem Pharmacolx,38(21):3791-3795.
TRAN T H, NGUYEN V T, LE H T, et al, 2021. Garcinoxanthones SV, new xanthone derivatives from the pericarps of Garcinia mangostana together with their cytotoxic and antioxidant activities[J]. Fitoterapia,151:104880.
WANG F, YAN J, NIU Y, et al, 2013. Mangiferin and its aglycone, norathyriol, improve glucose metabolism by activation of AMP-activated protein kinase[J]. Pharm Biolx, 52(1):68-73.
WANG H, YE G, Ma C H, et al, 2007. Identification and determination of four metabolites of mangiferin in rat urine[J]. J Pharm Biomed Analx, 45(5):793-798.
WANG J P, HO T F, LIN C N, et al, 1994. Effect of norathyriol, isolated from Tripterospermum lanceolatum, on A23187-induced pleurisy and analgesia in mice[J]. Naunyn Schmiedebergs Arch Pharmacol, 350(1):90-95.
WANG L W, KANG J J, CHEN I J, et al, 2002. Antihypertensive and vasorelaxing activities of synthetic xanthone derivatives[J]. Bioorg Med Chem,10(3):567-572.
XING H H, XIANG N J, LIU L X, et al, 2017. Two new xanthones from Swertia atroviolacea and their anti-5α-reductase activity[J]. Chem Nat Compd, 53(6):1052-1055.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构